Clinical Trial Update: ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases [Phase 3]

View source ↗

Summary

Phase 3 trial of ALD-101 as adjuvant therapy with unrelated umbilical cord blood transfusion in inherited metabolic diseases was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inborn Errors of Metabolism
• Inherited Metabolic Diseases
• Lysosomal Storage Disorders
• Mucopolysaccharidosis
• Peroxisomal Storage Diseases

Drugs mentioned

• ALD-101

Snippet

Sponsor: Aldagen | Conditions: Inherited Metabolic Diseases, Lysosomal Storage Disorders | Phase 3 | Status: TERMINATED